EU & National Funding for Public Health Research

Kay Duggan-Walls
National Contact Point, Horizon 2020 Health
National Focal Point, Public Health Programme

IPH Conference Belfast
11 October 2016
Brexit & EU funding

• The UK Government and the European Commission confirmed earlier in the summer that the UK EU referendum result had no immediate effect on UK organisations applying to or participating in Horizon 2020 and that they could continue to apply to the programme in the usual way.

• Statement from Jo Johnson, MP: https://www.gov.uk/government/news/statement-on-higher-education-and-res...


• In addition to these statements, we are pleased to inform you that the HM Treasury (the UK finance ministry) guaranteed that all UK organisations bidding individually or as members of consortia for Horizon 2020 projects, while the UK is still a member of the EU, will have certainty over future funding with the Treasury underwriting the payments of such awards, even when specific projects continue beyond the UK’s departure from the EU.

EU Public Health Programme

- Health programme is about fostering health in Europe by encouraging cooperation between member states to improve the health policies that benefit their citizens
- Aims to support and complement MS health initiatives

Objectives

I. Promote health & prevent diseases, foster supportive environments for healthy lifestyles
II. Protect Citizens from serious cross-border health threats
III. Contribute to innovative, efficient and sustainable health systems
IV. Facilitate access to better and safer healthcare for EU citizens
EU Public Health Programme

Project Grants

• Call open Spring 2017 - Deadline approx. 2-3 months
• [Link](http://ec.europa.eu/research/participants/portal/desktop/en/opportunities/3hp/calls/hp-pj-2016.html#c,topics=callIdentifier/t/HP-PJ-2016)
• Eligibility: 3 different partners from 3 different EU countries
• < 3 years duration
• Co-funding 60% eligible costs covered by EU contribution
• Migrants health, chronic diseases, smoking, alcohol (underage drinking), donation of blood, tissues and cells, frailty, healthcare associated infection, early diagnosis TB and hepatitis
• Recently funded project – HepCare Europe Hepatitis C – Jack Lambert, Mater Hospital, Walter Cullen, UCD, HSE - **€1.7 million**
EU Public Health Programme

• Joint Actions

Co-financed by competent authorities responsible for health in member states (DOH). Public sector bodies and non-governmental bodies mandated by DOH can also participate.

2016

• **Quality of HIV/AIDS/STI, viral Hepatitis and tuberculosis prevention and linkage to care** (€ 2 000 000 EU co-funding)

• **JA-02-2016 - Action on chronic diseases** (€ 5 000 000 EU co-funding)

• **JA-03-2016 - Tobacco control** (€ 2 000 000 EU co-funding)

• **JA-04-2016 - Antimicrobial resistance and Health Care Associated Infections** (€ 4 000 000 EU co-funding)

• **JA-05-2016 - Authorisation of preparation processes in blood and tissues and cells** (€ 800 000 EU co-funding)
EU Health Policy Platform

• New way of communicating between Commission services and health stakeholders & amongst stakeholders

• [https://webgate.ec.europa.eu/hpf/](https://webgate.ec.europa.eu/hpf/)

• Platform – Stakeholders discuss public health issues, jointly produce statements on subjects, share knowledge, promote events, exchange documents

• Regular meetings – twice/year face-to-face meetings
Horizon 2020 is the biggest EU Research and Innovation programme ever

€80 billion of funding available over 7 years (2014 to 2020)

It promises more breakthroughs, discoveries and world-firsts by taking great ideas from the lab to the market.
Horizon 2020 - Health Demographic Change and well being

- **2017 call** –
  SC-PM-03-2017 Diagnostic characterisation of rare diseases €15 M (budget €15 M), closing date: **11 Apr 2017, single-stage**
  SC-PM-11-2016-2017 Clinical research on regenerative medicine €4-6 M (budget €30M), closing date: **11th April 2017, Single-stage**
  SC-PM-15-2017 Personalised coaching for well-being of people as they age €3-4 M (budget €25 M), closing date: **31 Jan 2017, Single-stage**
  SC-PM-16-2017 In-silico trials for developing and assessing biomedical products€4-6M, (budget €19M), Closing date: **14 Mar 2017, Single-stage**
  SC- PM-17-2017 Personalised computer models and in-silico systems for well-being €4-6 M (budget €19 M), closing date: **14 Mar 2017, Single-stage**
  SC-PM-20-2017 Development of new methods and measures for improved economic evaluation and efficiency measures in the health sector (budget €9M), closing date: **11 Apr 2017, Single-stage**
Health Work Programme 2016/2017

• Topics are **Multidisciplinary**
• Opportunities for dissemination, communication and training activities
• Public engagement
• Work life, lifestyle aspects
• Patient involvement (caregivers also)
• Leisure, social participation
• User needs
• Ethics Issues
• Gender Issues
• Clinical, public health & socio-economic research, deployment of policy strategies, new technologies (e.g. ICT, social platforms, new types data geographical, genetic, eHealth records etc.

• Engage with international, national, regional authorities – ensure finding translated into policy

• Public engagement, dissemination, communication, training, policy, lifestyle management, environmental, occupational, epidemiological surveys, capacity building, best practice

• Involve patients & take their views into account wherever relevant

• Non-pharmacological therapies

• User acceptance of ICT based technologies, training of professionals, domestic rehabilitation (physical & cognitive), communication, patient consent

• Multidisciplinary research including behavioural, sociological, health

• Solutions should be: cost-effective, acceptable to end-users, applicable to realistic settings, driven by needs, interests & lifestyles of older people, reduction of isolation & loneliness, adaptation towards different histories & cultures across the EU

• Legal, ethical & social issues to be considered

• Its stated impact should be broad, addressing economic and social benefits & its effect on reducing inequalities. Proposals should be multidisciplinary
Birth Day Prize

Horizon Prize on reducing maternal and new-born morbidity and mortality - the Birth Day Prize

A novel solution is expected to improve the outcome of facility-based deliveries, which might be of a clinical, technological or managerial nature, or a combination of these. Any solution must take full account of relevant social factors and have the potential of scaling up rapidly.

Developed by European Commission and Bill & Melinda Gates Foundation

Deadline: Second quarter of 2017
Horizon 2020 Advisory Group Report
Calls 2018-2020

Vertical themes
1. Personalised Medicine
2. Rare Diseases
3. Infectious Diseases
4. Non-communicable Diseases
5. Paediatrics
6. Public Health and prevention including migration
7. Active and healthy ageing
Horizon 2020 Scoping paper (draft)
Calls 2018-2020

4 priorities

1. Better health and care, economic growth and sustainable health systems
   • Personalised Medicine
   • Innovative health and care industry
   • Improving global health
   • Sustainable and evidence-based health and care systems
   • Innovative health and care delivery services – integration of care

2. Decoding the role of the overall environment for health and well-being
   • The human exposome
   • Global changes and health (climate change, agri-food, migration)

3. Digital transformation in Health and care
   • ehealth and mhealth
   • ICT for Active and healthy ageing

4. Trusted Big Data solutions and Cybersecurity for Health and Care
   • Trusted Big Data solutions for health and care
   • Cybersecurity for health and care
Health Research Board Calls
## OPEN CALLS – INDICATIVE SCHEDULE 2016-2020

<table>
<thead>
<tr>
<th>Focus Area 1</th>
<th>2015</th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Investigator-led projects <em>(new)</em></td>
<td>1.1.1</td>
<td>✔️</td>
<td>✔️</td>
<td>✔️</td>
<td>✔️</td>
<td>✔️</td>
</tr>
<tr>
<td>HRB/MRCG Joint Funding Scheme</td>
<td>1.1.2</td>
<td>✔️</td>
<td>✔️</td>
<td>✔️</td>
<td>✔️</td>
<td>✔️</td>
</tr>
<tr>
<td>HRB/SFI Wellcome Biomedical Partnership</td>
<td>1.2.3</td>
<td></td>
<td></td>
<td>Rolling calls</td>
<td></td>
<td></td>
</tr>
<tr>
<td>US Ireland R&amp;D Partnership Awards</td>
<td>1.2.2</td>
<td></td>
<td></td>
<td>Rolling calls</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EU awards (e.g. JPIs / CSAs / ERA-Nets)</td>
<td>1.2.1</td>
<td></td>
<td></td>
<td>Rolling calls</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Focus Area 2

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Trial Networks</td>
<td>2.1.2</td>
<td>✔️</td>
<td>✔️</td>
<td>✔️</td>
<td>✔️</td>
<td>✔️</td>
</tr>
</tbody>
</table>

### Focus Area 3

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>RCQPS <em>(Collaboration in Quality &amp; Patient Safety)</em></td>
<td>3.1.2</td>
<td>✔️</td>
<td>✔️</td>
<td>✔️</td>
<td>✔️</td>
<td>✔️</td>
</tr>
<tr>
<td>CICER (NCEC/HRB Clinical Effectiveness Hub)</td>
<td>3.3.2</td>
<td>✔️</td>
<td>✔️</td>
<td>✔️</td>
<td>✔️</td>
<td>✔️</td>
</tr>
<tr>
<td>Implementation Research <em>(In development)</em></td>
<td>3.1</td>
<td></td>
<td></td>
<td>To be determined</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Knowledge dissemination</td>
<td>3.1.3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Enabler A

<table>
<thead>
<tr>
<th>PhD training in patient oriented research <em>(new)</em></th>
<th>A.1.1</th>
<th>✔️</th>
<th>✔️</th>
<th>✔️</th>
<th>✔️</th>
<th>✔️</th>
</tr>
</thead>
<tbody>
<tr>
<td>Postdoctoral awards</td>
<td>A.2.1</td>
<td></td>
<td></td>
<td>✔️</td>
<td>✔️</td>
<td>✔️</td>
</tr>
<tr>
<td>Emerging Investigators <em>(new)</em></td>
<td>A.2.4</td>
<td></td>
<td></td>
<td>✔️</td>
<td>✔️</td>
<td>✔️</td>
</tr>
<tr>
<td>Senior Investigators</td>
<td>A.3.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Summer Scholarships</td>
<td>A.4.2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cancer nursing project development grant</td>
<td>A.4.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Short training courses (e.g. NCI Cancer Prev. F’ship)</td>
<td>A.4.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Enabler B

<table>
<thead>
<tr>
<th>PPI <em>(new)</em></th>
<th>B.2.1</th>
<th>✔️</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biobanking support <em>(new)</em></td>
<td>B.4.2</td>
<td></td>
</tr>
</tbody>
</table>

*New call under consideration*
For further information contact

Kay Duggan-Walls
kdugganwalls@hrb.ie
tel (01) 2345 187